T 2034/21 (Combination immunotherapy/SLOAN-KETTERING) of 09.03.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T203421.20230309
- Date of decision
- 9 March 2023
- Case number
- T 2034/21
- Petition for review of
- -
- Application number
- 10821297.8
- IPC class
- C07K 16/28A61P 35/00A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Combination immunotherapy for the treatment of cancer
- Applicant name
- Memorial Sloan-Kettering Cancer Center
Board of Regents, The University of Texas System - Opponent name
- GlaxoSmithKline Intellectual Property Development Limited
Kymab Limited - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Main request: Amendments - added subject-matter (yes)
Auxiliary request 1: Amendment to case - reasons for submitting amendment in appeal proceedings (no)
Auxiliary requests 2 to 10: Amendments - added subject-matter (yes) - Catchword
- -
- Citing cases
- T 0405/24
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.